Henry Kuhns, MD
Internal Medicine · El Dorado, KSNPI 1699797878
Payments from drug & device makers
Across 251 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$678
- AbbVie$459
- AstraZeneca$341
- Sumitomo Pharma America, Inc.$243
- Pfizer$223
- Amgen$222
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,132100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $678 |
| AbbVie(2 entities) | 29 | $459 |
| AstraZeneca | 21 | $341 |
| Sumitomo Pharma America, Inc. | 11 | $243 |
| Pfizer | 13 | $223 |
| Amgen(2 entities) | 13 | $222 |
| Abbott | 12 | $216 |
| Lilly USA, LLC | 14 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $198 |
| Amarin Pharma, Inc. | 10 | $162 |
| Bayer | 9 | $139 |
| Boehringer Ingelheim | 6 | $99 |
| Merck | 6 | $88 |
| GSK | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Johnson & Johnson | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Insulet Corporation | 4 | $65 |
| Corium, LLC | 2 | $43 |
| Dexcom, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Novartis | 2 | $35 |
| Verona Pharma, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Medtronic | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$4,146 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 196 | $219,012 |
| EliquisApixaban | 211 | $143,470 |
| MounjaroTirzepatide | 108 | $123,673 |
| JardianceEmpagliflozin | 105 | $94,027 |
| FarxigaDapagliflozin Propanediol | 65 | $53,296 |
| XareltoRivaroxaban | 47 | $43,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $29,286 |
| JanuviaSitagliptin Phosphate | 43 | $27,089 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $17,644 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $17,155 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $17,007 |
| GemtesaVibegron | 38 | $16,979 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $13,525 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,255 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 96 | $11,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $678 | $219,012196 claims |
| PfizerEliquis, Paxlovid | $223 | $146,328234 claims |
| Lilly USA, LLCMounjaro | $206 | $123,673108 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $99 | $107,858131 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $341 | $71,481107 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $88 | $67,315138 claims |
| Johnson & JohnsonXarelto | $72 | $43,28447 claims |
| MerckJanuvia | $88 | $27,08943 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $243 | $16,97938 claims |
| NovartisEntresto | $35 | $7,76412 claims |
| AbbVieSynthroid | $459 | $3,40555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in El Dorado
- Amy SeeberEl Dorado$7K
- Allison SolloEl Dorado$7K
- Kyle TiptonEl Dorado$6K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.